Terms: = Endocrine gland cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
3677 results:
1. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
[TBL] [Abstract] [Full Text] [Related]
2. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract] [Full Text] [Related]
3. Targeting kras in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
4. The pRb/RBL2-E2F1/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry/exit by paracrine mechanisms.
Chang CH; Liu F; Militi S; Hester S; Nibhani R; Deng S; Dunford J; Rendek A; Soonawalla Z; Fischer R; Oppermann U; Pauklin S
Nat Commun; 2024 Apr; 15(1):3580. PubMed ID: 38678032
[TBL] [Abstract] [Full Text] [Related]
5. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing.
Lahusen A; Cai J; Schirmbeck R; Wellstein A; Kleger A; Seufferlein T; Eiseler T; Lin YN
Sci Rep; 2024 Apr; 14(1):9377. PubMed ID: 38654067
[TBL] [Abstract] [Full Text] [Related]
6. Targeting kras in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract] [Full Text] [Related]
7. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating kras-c-RAF dependent PDAC.
Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
[TBL] [Abstract] [Full Text] [Related]
8. A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
Kong LR; Gupta K; Wu AJ; Perera D; Ivanyi-Nagy R; Ahmed SM; Tan TZ; Tan SL; Fuddin A; Sundaramoorthy E; Goh GS; Wong RTX; Costa ASH; Oddy C; Wong H; Patro CPK; Kho YS; Huang XZ; Choo J; Shehata M; Lee SC; Goh BC; Frezza C; Pitt JJ; Venkitaraman AR
Cell; 2024 Apr; 187(9):2269-2287.e16. PubMed ID: 38608703
[TBL] [Abstract] [Full Text] [Related]
9. Genetic Signature of Human Pancreatic cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract] [Full Text] [Related]
10. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer.
Fu J; Ling J; Li CF; Tsai CL; Yin W; Hou J; Chen P; Cao Y; Kang Y; Sun Y; Xia X; Jiang Z; Furukawa K; Lu Y; Wu M; Huang Q; Yao J; Hawke DH; Pan BF; Zhao J; Huang J; Wang H; Bahassi EIM; Stambrook PJ; Huang P; Fleming JB; Maitra A; Tainer JA; Hung MC; Lin C; Chiao PJ
Nat Commun; 2024 Apr; 15(1):3149. PubMed ID: 38605037
[TBL] [Abstract] [Full Text] [Related]
11. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
12. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
13. Macrophage-induced reactive oxygen species in the initiation of pancreatic cancer: a mini-review.
Döppler HR; Storz P
Front Immunol; 2024; 15():1278807. PubMed ID: 38576613
[TBL] [Abstract] [Full Text] [Related]
14. Advances in Systemic Therapy in Pancreatic cancer.
Yu KH
Hematol Oncol Clin North Am; 2024 Jun; 38(3):617-627. PubMed ID: 38575456
[TBL] [Abstract] [Full Text] [Related]
15. STAT3 is a genetic modifier of TGF-beta induced EMT in kras mutant pancreatic cancer.
D'Amico S; Kirillov V; Petrenko O; Reich NC
Elife; 2024 Apr; 13():. PubMed ID: 38573819
[TBL] [Abstract] [Full Text] [Related]
16. IL-2 promotes expansion and intratumoral accumulation of tumor infiltrating dendritic cells in pancreatic cancer.
Gong T; Huang X; Wang Z; Chu Y; Wang L; Wang Q
Cancer Immunol Immunother; 2024 Mar; 73(5):84. PubMed ID: 38554155
[TBL] [Abstract] [Full Text] [Related]
17. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.
Hrudka J; Kalinová M; Ciprová V; Moravcová J; Dvořák R; Matěj R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542259
[TBL] [Abstract] [Full Text] [Related]
18. Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer.
Cortesi A; Gandolfi F; Arco F; Di Chiaro P; Valli E; Polletti S; Noberini R; Gualdrini F; Attanasio S; Citron F; Ho IL; Shah R; Yen EY; Spinella MC; Ronzoni S; Rodighiero S; Mitro N; Bonaldi T; Ghisletti S; Monticelli S; Viale A; Diaferia GR; Natoli G
Sci Adv; 2024 Mar; 10(13):eadk5386. PubMed ID: 38536927
[TBL] [Abstract] [Full Text] [Related]
19. Evolution of Testicular Germ Cell Tumors in the Molecular Era With Histogenetic Implications.
Kilic I; Acosta AM; Idrees MT
Adv Anat Pathol; 2024 May; 31(3):206-214. PubMed ID: 38525515
[TBL] [Abstract] [Full Text] [Related]
20. Combined kras-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
Bulle A; Liu P; Seehra K; Bansod S; Chen Y; Zahra K; Somani V; Khawar IA; Chen HP; Dodhiawala PB; Li L; Geng Y; Mo CK; Mahsl J; Ding L; Govindan R; Davies S; Mudd J; Hawkins WG; Fields RC; DeNardo DG; Knoerzer D; Held JM; Grierson PM; Wang-Gillam A; Ruzinova MB; Lim KH
Nat Commun; 2024 Mar; 15(1):2503. PubMed ID: 38509064
[TBL] [Abstract] [Full Text] [Related]
[Next]